Loading
A phase 2 trial of cemiplimab in lung cancer, run by University of Maryland, Baltimore, not yet recruiting.
Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial is a phase 2, interventional study registered as NCT07746388 by University of Maryland, Baltimore, with a registry enrolment figure of 30 participants, started 2026-09-01 and due to reach its primary completion in 2030-09-01. Interventions recorded: Cemiplimab. Conditions listed: Nsclc; NSCLC Stage II; NSCLC, Stage III; NSCLC Stage IIIB; Resectable Lung Non-Small Cell Carcinoma. Primary outcome: Major pathologic response (MPR). Lung eligibility wording from the registry: "Participants with histologically confirmed stage II-IIIB(N2) NSCLC (per the 9th International Association for the Study of Lung Cancer) with disease that is considered resectable prior to initiation of systemic therapy". No results are recorded here; the registry entry is the source.
Shares Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Regeneron, Cemiplimab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Regeneron, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Regeneron, Cemiplimab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.